SAMiRNA-AREG

N/A

Report date: 2025/06/11 20:01:15

NME

Base Information

Drug NameSAMiRNA-AREG

Drug Alias NameAB-02 program (Sirnagen Therapeutics)AB-03 program (Sirnagen Therapeutics)AB-06 program (Sirnagen Therapeutics)AB-07 program (Sirnagen Therapeutics)AB-08C program (Sirnagen Therapeutics) +[14]

ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA

Mechanisms of ActionFibroblast stimulants

TargetsUpdating

Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Diabetic hypertensionCicatrix +[17]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryAustralia and New ZealandSouth Korea

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniessiRNAgen Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniessiRNAgen Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsCoronavirus Disease 2019 (COVID-19)Diabetic hypertensionCicatrix +[17]

Inactive IndicationsN/A

Other Information

ATC CodeN/A